Dynavax (DVAX) – Press Releases
-
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
-
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
-
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
-
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
-
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
-
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
-
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
-
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
-
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
-
Dynavax to Present at Upcoming Investor Conferences
-
Dynavax to Present at the JMP Securities Life Sciences Conference
-
Dynavax Reports First Quarter 2023 Financial Results
-
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
-
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
-
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
-
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine
-
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
-
Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
-
Dynavax Announces Uplisting to the Nasdaq Global Select Market
-
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
-
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
-
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
-
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
-
Dynavax to Present at Two Upcoming Investor Conferences
-
Dynavax Reports Third Quarter 2022 Financial Results
-
Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022
-
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference
-
Clover Provides Update on 2022 Corporate Milestones
-
Clover Provides Update on 2022 Corporate Milestones
-
Valneva Provides Further Update on its COVID-19 Activities
-
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
-
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
-
Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
-
Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
-
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
-
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine
-
Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
-
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
-
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
-
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001
-
Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
-
Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
Back to DVAX Stock Lookup
